Closing in on midday, BioNTech stock price sits at $91. To begin with, BioNTech seems to have a respectable ROE. Be that as it may, the company's ROE is still quite lower than the industry average of 17%. Still, we can see that BioNTech has seen a remarkable net income growth of 54% over the past five years. We believe that there might be other aspects that are positively influencing the company's earnings growth. For instance, the company has a low payout ratio or is being managed efficiently. Bear in mind, the company does have a respectable ROE. It is just that the industry ROE is higher. So this certainly also provides some context to the high earnings growth seen by the company. "[BioNTech] found an asset, they developed it, and then they got a pharma partner, it's like a dream," said BMO analyst Evan David Seigerman. "So they're really strategic in that, and I think they're adding a lot of diversification, which makes the story a lot less risky if you're just focused on mRNA, vaccines and Covid, and that's super risky, in my view." BioNTech stock price at $90.72 shows mild pullback from recent highs. Sector-wide valuations remain stretched, but relative strength could protect against sharp downturns if healthcare spending projections hold.